Canaccord Genuity Remains Bullish on ATARA Biotherapeutics (ATRA)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Cowen Starts Atara Biotherapeutics (ATRA) at Outperform
January 26, 2018 5:42 AM ESTCowen initiates coverage on Atara Biotherapeutics (NASDAQ: ATRA) with an Outperform rating.
Analyst Eric Schmidt highlights that ATRA creates novel, off-the-shelf T cell therapies for treating cancer, viral infections, and autoimmune disorders. Lead candidate tab-cel is in pivotal study for EBV+ PTLD, a... More
